Original Research Article

Anti-diabetic potential of *Plectranthus lanuginosus* in streptozotocin-induced diabetic rats

Mohammed H Mukhtar¹, Waleed H Almalki², Muhammad Ahmed², Aisha Azmat³

¹Department of Biochemistry, Faculty of Medicine, ²Department of Pharmacology, Faculty of Pharmacy, ³Department of Physiology, Faculty of Medicine, Umm Al Qura University, Makkah, Saudi Arabia

*For correspondence: Email: hma00ahmed@hotmail.com; Tel: 00966-556618257

Sent for review: 11 March 2019  Revised accepted: 24 September 2019

**Abstract**

**Purpose:** To determine the antidiabetic effect of methanol extract of *Plectranthus lanuginosus* leaves in streptozotocin-induced hyperglycemic (HGD) rats.

**Methods:** *P. lanuginosus* leaves were collected from Saad Medhas, Al Baha, Kingdom of Saudi Arabia. After defatting with n-hexane, they were extracted in vacuo at 40 °C with 75% methanol. Streptozotocin (50 mgkg⁻¹, i.p.) was used to induce hyperglycemia (diabetes) in the rats. The HGD rats received either standard drug (glibenclamide, 10 mgkg⁻¹, p.o.) or *Plectranthus lanuginosus* leaf methanol leaf extract (PLLM) at doses of 200 and 400 mgkg⁻¹/day, p.o. for 21 consecutive days. Blood samples were taken from the rat tails 2 h after dosing, and at 7-day intervals (i.e., 0, 7th, 14th and 21st days). The blood samples were used for measurement of fasting blood glucose (FBG), and serum lipid profile (cholesterol, triglycerides, HDL and LDL) were determined using a hemolyzer.

**Results:** Streptozotocin treatment produced significant hyperglycemia in the rats (348.9 ± 5.6) when compared to control (79.2 ± 1.3). However, PLLM (200 and 400 mg kg⁻¹) produced significant and dose-dependent anti-diabetic (166.4 ± 5.6 and 123.86 ± 6.8 respectively) and antihyperlipidemic effects in HGD rats, at levels similar to those produced by the standard drug, glibenclamide (120.6 ± 6.4).

**Conclusion:** *P. lanuginosus* leaf extract possesses pronounced anti-diabetic and anti-hyperlipidemic properties which may be due to the presence of phenolic and flavonoid constituents in the plant. Therefore, the plant extract can be further developed for the management of diabetes.

**Keywords:** *Plectranthus lanuginosus*, Antidiabetic effect, Flavonoids, hyperglycemic (diabetic: HGD) rats

This is an Open Access article that uses a fund-ing model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

Tropical Journal of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals (DOAJ), African Journal Online, Bioline International, Open-J-Gate and Pharmacy Abstracts

**INTRODUCTION**

Diabetes mellitus (DM) is a metabolic ailment diagnosed as FBS ≥ 7.0 mmol/L⁻¹ (126 mg/dL), random blood glucose (RBS) ≥ 11.1 mmol/L (200 mgdL⁻¹), and glycated hemoglobin (HbA₁C) ≥ 48 mmol/mol (≥ 6.5 DCCT %) [1]. The incidence of DM is on the increase, and it has been estimated that by the year 2030, approximately 472 million people in the world...
**Experimental animals**

In-bred 2-month-old Sprague Dawley (SD) rats of both sexes (weighing 220 – 260 g) were used in the entire study. The rats were reared in the premises of the Faculty (Umm Al Qura University, Faculty of Pharmacy, Makkah, KSA) with fresh and balanced diet, and clean water was provided. Prior to STZ treatment, the rats were fasted overnight, but were permitted free access to clean drinking water. This study was executed according to the international regulations for the use of animals [10]. The experimental protocol was approved by the Animal Ethics Committee of Faculty of Medicine, Umm Al Qura University, Makkah, Saudi Arabia (ethical approval no. UQU-COP-EA#14341).

**Oral acute toxicity study**

Oral toxicity test (acute) for PLLM was done using fresh and healthy rats (3 rats), following the Organization of Economic Cooperation and Development (OECD) Guideline 423. For this purpose, maximum limit dose of PLLM (2 g/kg) was administered orally using gavage. Noxious and toxic signs and/or mortality were recorded during the first 2 h after dosing. Then, the animals were monitored for the next 48 h. Their body weights were recorded for 14 days. The extract was found safe at PLLM exposure levels up to a dose of 2g/kg. Thus, PLLM doses of 200 and 400 mg/kg were selected for use in subsequent studies on the antidiabetic effect of the extract.

**Anti-diabetic evaluation of PLLM**

Healthy male adult rats (200 ± 10 g body weight) were randomly selected. Thirty rats were divided equally into five groups as shown in Table 1.

| Rat group | Description | Treatment |
|-----------|-------------|-----------|
| I         | Normal control | Distilled water |
| II        | HGD rats (positive control) | Distilled water |
| III       | HGD rats | Glibenclamide (10 mgkg⁻¹) |
| IV        | HGD rats | PLLM (200 mgkg⁻¹) |
| V         | HGD rats | PLLM (400 mgkg⁻¹) |

Diabetes mellitus was induced in the rats using STZ (except group 1). For induction of DM, the rats were intra-peritoneally injected freshly prepared STZ solution in cold citrate buffer, pH 4.5 [11]. After 48 h, FBS levels were measured using a Bayer Contour Blood Glucose Meter.
(Germany), and rats with FBS $> 200$ mg/dL were deemed diabetic [12]. The diabetic rats (groups III to V) were given PLLM extract or standard drug (glibenclamide) using oral gavage once a day for 21 consecutive days. Blood samples were taken through the tail tips at 2 h after dosing, and subsequently at 7-day intervals i.e. at 0, 7th, 14th, and 21st days. Blood glucose level was determined in each sample with a glucometer [13]. On the 21st day, 5 - 8 ml blood sample was withdrawn directly from all experimental groups through cardiac puncture, and sera were separated [13]. The serum samples were used for estimation of various biochemical parameters, as indicated hereunder.

### Biochemical analyses

Blood samples (obtained via cardiac puncture) were centrifuged at 3500 rpm for 15 mins. Liver function biomarkers: aspartate aminotransferase (SGOT) and serum glutamic pyruvic transaminase (SGPT), and lipid profile (triglycerides, total cholesterol, VLDL, and HDL-cholesterol) were assayed using HumaLyzer 3000.

### Statistical analysis

Data are presented as mean ± standard error means (SEM). For further interpretation, one-way analysis of variance (ANOVA) was done, followed by Tukey's multiple comparison tests, on Minitab 17.

### RESULTS

#### Oral acute toxicity

The extract (PLLM) was non-toxic up to a dose of 2000 mg kg$^{-1}$. For acute toxicity, the physical and emotional behaviors of the rats were continuously monitored for the first 2 h, after which the rats were observed after 8 h, and then every 8 h during the next 48 h. The extract did not cause any significant changes in the animals' normal behavior, nor did it produce any mortality.

#### Anti-diabetic effect of PLLM

The results are presented in Table 2. The HGD rats (positive control: group II) exhibited a significant increase in FBS ($p<0.001$) throughout the study period (21 days). The reference drug (glibenclamide, 10 mgkg$^{-1}$/day) and PLLM (200 and 400 mgkg$^{-1}$/day) produced significant and dose-dependent declines in FBS levels, relative to diabetic control rats on the 7th, 14th, and 21st days. A significant anti-diabetic effect was observed after 14 consecutive days of administration of glibenclamide and PLLM (200 and 400 mgkg$^{-1}$). Group IV (PLLM 400 mgkg$^{-1}$) showed noticeable improvement in diabetic status from the first week of the drug administration onwards (Table 2). With continuous treatment till the 21st day, the high dose of PLLM (400 mgkg$^{-1}$) and glibenclamide (10 mgkg$^{-1}$) reversed the STZ-induced hyperglycemia to normal levels, as shown in Table 2. As presented in Table 3, there were significant elevations in total cholesterol, LDL and triglycerides, and a significant decrease in HDL cholesterol in the HGD rats (group II), when compared with control (group I). However, continuous treatment with PLLM (groups III and IV) and glibenclamide (group V) for 21 days produced significant alterations in lipid levels ($p < 0.05$). The SGPT and SGOT levels were also normal in PLLM- and glibenclamide-treated rats, but the diabetic control rats had significant elevations in the levels of SGPT and SGOT ($p < 0.001$).

### DISCUSSION

Diabetes mellitus (DM) is the fastest growing disorder in KSA [14], with heightened possibility of high level of mortality and huge medical expenditure [15]. Diabetes increases the risk of other disorders like cardiovascular disease, neuropathy, retinopathy and nephropathy, which are the most common complication of diabetes [16]. Thus, there is need for concerted research efforts to evolve effective therapy for the disease [17].

#### Table 2: Effect of PLLM on blood glucose levels in STZ-induced diabetic rats

| Treatment/group | 0 day             | 7th day          | 14th day          | 21st day           |
|-----------------|-------------------|------------------|-------------------|-------------------|
| Control         | 79.6±1.28         | 75.28±1.0        | 80.26±1.56        | 79.21±1.3         |
| Diabetic control| 280.2±2.98**      | 298.19±2.15**    | 314.72±2.16**     | 348.89±3.66**     |
| PLLM 200mgkg$^{-1}$| 278.2±3.78       | 246.6±1.29*      | 236.3±3.83*       | 166.36±5.62*      |
| PLLM 400mgkg$^{-1}$| 270.93±1.67      | 212.3±2.56*      | 199.63±2.4*       | 123.86±6.78*      |
| Glibenclamide (10mgkg$^{-1}$)| 275.36±3.65 | 238.6±3.38* | 200.8±3.65* | 120.56±6.36* |

Values are presented as mean ± SEM (n = 8); *$p < 0.01$, compared with HGD rats; **$p < 0.01$, compared with control rats.
Alternative herbal medicines are used in different countries for DM, but most of these herbal remedies have not been scientifically investigated. It is necessary to study such medicinal plants because they might contribute to the development of newer drugs/compounds for inclusion in the diabetologist’s pharmacy.

Many species of *Plectranthus* are being used as alternative treatments for DM [18]. The antidiabetic effect of PLLM was assessed in the present study because the genus *Plectranthus* is a significant, prolific and extensively used genus in folkloric medicine in southern Africa [18].

In the current work, the two PLLM doses (200 and 400 mg kg^{-1}) exhibited significant and dose-dependent blood glucose-lowering effects (anti-diabetic activity) against STZ-induced DM in rats. This anti-diabetic response in PLLM-treated rats was similar to that produced with the standard drug glibenclamide. It is known that STZ produces hyperglycemia due to its cytotoxic effect on the beta cells of the pancreas [19]. However, in STZ-treated rats, PLLM significantly reduced the blood glucose level.

In earlier studies on *Plectranthus amboinicus* using a dose of 400 mg kg^{-1}, it was suggested that the significant anti-diabetic effects in rats might be due to individual or synergistic action of flavonoids and other bioactive phytoconstituents present in *Plectranthus* [18]. Another study also revealed the antidiabetic potential of *Plectranthus esculentus* in STZ-induced hyperglycemic rats [19].

In past studies, different extracts from different species of *Plectranthus* were reported to exert anti-diabetic effects against STZ- and alloxan-induced diabetes in different animal models. The findings in the current study on the anti-diabetic effect of PLLM (200 and 400 mg kg^{-1}) are in agreement with those reported in earlier studies. Plants that contain flavonoids, terpenoids, alkaloids, and glycosides possess antidiabetic and antioxidant potential. Flavonoids rejuvenate injured pancreatic beta cells, while saponins inhibit normal glucose transport by blocking the intestinal sodium-glucose co-transporter-1 (SGLUT-1) [20,21]. Earlier studies have reported the presence of tannins, flavonoids and saponins in *Plectranthus* [22]. Thus, the antidiabetic effect of PLLM might be due to the presence of flavonoids and saponins in the extract.

Hypercholesterolemia and hyper-triglyceridemia are major complications of DM [23]. The significant fall in lipid profile (serum total cholesterol, triglycerides and LDL-cholesterol), while the concomitant increase in serum HDL-cholesterol levels in the PLLM-treated diabetic rats, are strongly indicative of the anti-hyperlipidemic potential of PLLM. Research has revealed that phenolics have considerable antioxidant potential and, by inhibiting the activities of α-glucosidase and α-amylase, they downregulate carbohydrate metabolism [24]. Furthermore, polyphenols act on cardiovascular system in DM and rectify the metabolism of lipoproteins and lipids, eventually reversing hyperlipidemia [25]. The presence of phenolic constituents in *Plectranthus* could be one of the reasons for the higher anti-diabetic and anti-hyperlipidemic actions of this plant.

### CONCLUSION

The results obtained in this study indicate that PLLM exhibits anti-diabetic effect against STZ-HGD in rats. It further ameliorates hyperlipidemia in diabetic rats. These effects may be due to its contents of flavonoids, saponins and phenolic compounds. Thus, the plant has potential for development as a potential phytomedicine for the cure of DM.

### DECLARATIONS

#### Acknowledgement

The authors would like to thank the Institute of Scientific Research and Revival of Islamic Heritage for providing financial support through grant no.43310006, and Umm Al Qura University Makkah, KSA for their support during this research.
Conflict of interest

No conflict of interest is associated with this study.

Contribution of authors

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. All listed authors read and approved the submission of manuscript for publication. The author also declares that that manuscript data, or part thereof has not been submitted to any other journal.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus [published correction appears in Diabetes Care. 2010 Apr;33(4):e57]. Diabetes Care. 2010; 33 Suppl 1(Suppl 1):S62–S69. doi:10.2337/dc10-S062
2. Sherif S, Sumpio BE. Economic development and diabetes prevalence in MENA countries: Egypt and Saudi Arabia comparison. World J Diabetes 2015; 6(2): 304-311.
3. Parasuraman S, Kumar E, Kumar A, Emerson S. Free radical scavenging property and diuretic effect of triglize, a polyherbal formulation in experimental models. J Pharmacol Pharmacother. 2010; 1: 87-93.
4. Petchi RR, Parasuraman S, Vijaya C. Antidiabetic and antihyperlipidemic effects of an ethanolic extract of the leaves of Phygelius aequalis N.E.Br on hyperglycemia, antioxidant activity and lipid metabolism in streptozotocin-induced diabetic rats. J Ethnopharmacol 2010; 8: 187-194.
5. Hafizur RM, Babiker R, Yagi S, Chishti S, Kabir N, Choudhary MI. The antidiabetic effect of Geigeria alata is mediated by enhanced insulin secretion, modulation of β-cell function, and improvement of antioxidant activity in streptozotocin-induced diabetic rats. J Endocrinol, 2012; 214: 329-335
6. Ahmad M, Zaman F, Sharif T, Zabta MC. Antidiabetic and hypolipidemic effects of aqueous methanolic extract of Acacia nilotica pods in alloxan-induced diabetic rabbits. Scand J Lab Anim Sci 2008; 35: 29–34
7. Gaber KE, Singhai U, Daowd O. Hypoglycemic and hypolipidemic effects of some common plants extract in Type 2 diabetic patients at Eldabba area (North Sudan). IOSR J Pharm Biol Sci 2013; 8: 38–43
8. Hamill FA, Apio S, Mubiru NK, Bukunya-Zriba R, Mosango M, Maganyi OW, Soejarto DD. Traditional herbal drugs of Southern Uganda (II). Literature analysis and antimicrobial assays. J Ethnopharmacol 2003; 84: 57–78.
9. Camara CC, Nascimento NR, Macedo-Filho CL, Almeida FB, Fonteles MC. Antispasmodic effect of the essential oil of Plectranthus barbatus and some major constituents on the guinea-pig ileum. Planta Med 2003; 69: 1080–1085
10. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010; 8: 1-7.
11. Rabbani SI, Devi K, Khanam S. Protective role of glibenclamide against nicotinamide-streptozotocin induced nuclear damage in diabetic Wistar rats. J Pharmacol Pharmacother. 2010; 1: 18–23.
12. Liu Z, Li J, Zeng Z, Liu M, Wang M. The antidiabetic effects of cysteinyl metformin, a newly synthesized agent, in alloxan- and streptozocin-induced diabetic rats. Chem Biol Interact. 2008; 173: 68–75.
13. Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J Pharmacol Pharmacother. 2010; 1: 87–93.
14. Al-Nozha MM, Al-Maalouq MA, Al-Mazrouo YY, Al-Harthi SS, Arafah MR, Khalil MZ, Khan NB, Al-Khadra A, Al-Marzouki K, Nouh MS, Abdullah M, Attas O, Al-Shahid MS, Al-Mobeireek A. Diabetes mellitus in Saudi Arabia. Saudi Med J 2004; 25(11): 1603-1610
15. Alhowski AK. Economic costs of diabetes in Saudi Arabia. JFCM 2013; 20(1): 1–7.
16. Sarwar N, Gao P, Seshasai SR, Gibson R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. "Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies". Lancet 2010; 375(9733): 2215–2222.
17. Vishwakarma SL, Rakesh S, Rajmani M, Goyal RK. Evaluation of effect of aqueous extract of Encostemma litorale Blume. In streptozotocin induced type 1 diabetic rats. Indian J Exp Biol 2010; 48: 26–30.
18. Eleazu CO, Eleazu KC, Chukwuma SC, Okoronkwo J, Emelike CU. Effect of livingstonepota (Plectranthus esculentus N.E.Br) on hyperglycemia, antioxidant activity and lipid metabolism of streptozotocin induced diabetic rats. Toxicol Rep 2014; 1: 674–681.
19. Graham ML, Janecek JL, Kittredge JA, Hering BJ, Schuurman HJ. The streptozotocin-induced diabetic...
nude mouse model: Differences between animals from different sources. Comp Med. 2011; 61: 356–360.
20. Hakkim FL, Girija S, Kumar RS, Jalaluddeen MD. Effect of aqueous and ethanol extracts of Cassia auriculata L. flowers on diabetes using alloxan induced diabetic rats. Int J Diabetes Metab. 2007; 15: 100–106.
21. Tiwari AK, Rao JM. Diabetes mellitus and multiple therapeutic approaches of phytochemicals: Present status and future prospects. Curr Sci. 2002; 83: 30–38.
22. Asiimwe S, Borg-Karlsson AK, Azeem M, Mugisha KM, Namutebi A, Gakunga NJ. Chemical composition and Toxicological evaluation of the aqueous leaf extracts of Plectranthus amboinicus (Lour.) Spreng. Int. J. Pharm. Sci. Invent. 2014; 3: 19–27
23. Onunogbo C, Ohaeri OC, Eleazu CO, Eleazu KC. Chemical composition of mistletoe extract (Loranthus micranthus) and its effect on the protein, lipid metabolism and the antioxidant status of alloxan induced diabetic rats. J. Med. Res 2012; 1(4): 057–063
24. Iwai K. Anti-diabetic and antioxidant effects of polyphenols in brown alga Ecklonia stolonifera in genetically diabetic KK-A(y) mice. Plant Foods Hum. Nutr 2008; 63: 163–169
25. Zahra B, Parvin M, Fereidoun A. Dietary polyphenols as potential nutraceuticals in management of diabetes: a review J. Diab. Metab. Disord 2013; 12: 43-82